- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN
AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., a developer of novel cancer therapeutics, will be presenting a scientific poster at the Fourth International Conference on Tumor Microenvironment, which runs from March 6th to 10th in Florence, Italy.
The conference, hosted by the International Cancer Microenvironment Society, is a premier gathering of international cancer researchers who seek to develop cancer therapies targeting microenvironmental factors that control tumor growth and metastasis.
The poster, titled "L-DOS47 - a tumor microenvironment alkalization agent and a novel lung adenocarcinoma specific therapeutic candidate," provides a summary of selected L-DOS47 previously announced findings. Included in the poster are laboratory data showing the ability of L-DOS47 to bind to and destroy lung cancer cells alone and synergistically with selected chemotherapeutic drugs. Also being presented are mass tissue sample screening data, which show that L-DOS47 binds not only to primary lung adenocarcinoma tissues preferentially over a host of other cancerous or normal tissues, but also to metastasized cells in lymph nodes. The poster also highlights the ability of L-DOS47 to localize and concentrate in tumor tissues specifically following injection into laboratory animals
A copy of the poster will be available on Helix's website for download at http://www.helixbiopharma.com.
For additional information on the Tumor Microenvironment conference, please visit http://cancermicroenvironment.tau.ac.il/meeting-2007.html
L-DOS47 combines Helix's proprie
tary DOS47 new drug candidate
with a highly specific single domain antibody, to form a potential
new targeted drug product for the treatment of adenocarcinoma of
the lung, the most common form of cancer in the world today.
L-DOS47 is thought to function by leveraging a
natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the TSX under the symbol "HBP".
The Toronto and Frankfurt Stock Exchanges have not reviewed and
do not accept responsibility for the adequacy or accuracy of the
content of this News Release. Helix disclaims responsibility for
information contained in the Tu
mor Microenvironment conference
website, and the reference to such website in this News Release
does not constitute an endorsement by Helix of that or any other
website. This News Release contains certain forward-looking
statements regarding potential cancer therapeutics under
development by the Company, and in particular, regarding L-DOS47.
Forward-looking statements can be identified by the use of
forward-looking terminology such as "potential", "is thought", "is
believed", "new", "will", "theorized", or variations thereon or
comparable terminology referring to future events or results.
Forward looking statements are statements about the future and are inherently uncertain, and Helix's
actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, uncertainty whether L-DOS47 will be developed successfully as a drug or at all; uncertainty whether DOS47 will be developed as a therapeutic for any other cancers; research & development risks, including the risk that early R&D results may not be repeated in later R&D; the risk of technical obsolescence; the need for regulatory approvals, which may not be obtained in a timely matter or at all; the need for clinical trials, the occurrence and success of which cannot be assured; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; Helix's need for additional future capital, which may not be available in a timely manner or at all, as well as a description of other risks and uncertainties affecting Helix and its business, as contained in Helix's latest Annual Information Form and other filings with the Canadian
Securities Regulatory Authorities at www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future re sults. Forward-looking statements are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, opinions or expectations, or other circumstances change.
For further information: Investor Relations, Christina Bessant,
Group Inc., Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax: (416) 815-0080,
Email: email@example.com; Media Relations, Matthew Haines, Noonan
Russo, Tel: (212) 845-4235, Fax: (212) 845-4260, Email: